Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: After-Hours Movers » 19:08
05/11/20
05/11
19:08
05/11/20
19:08
CBAY

CymaBay

$1.84 /

+0.045 (+2.51%)

, IIVI

II-VI

$36.29 /

+0.45 (+1.26%)

, VRRM

Verra Mobility

$9.12 /

+0.08 (+0.88%)

, SGRY

Surgery Partners

$10.82 /

-0.12 (-1.10%)

, GDOT

Green Dot

$30.78 /

-0.73 (-2.32%)

, GO

Grocery Outlet

$36.71 /

+0.01 (+0.03%)

, CZR

Caesars

$9.65 /

-0.06 (-0.62%)

, NVAX

Novavax

$24.59 /

+5.86 (+31.29%)

, AMC

AMC Entertainment

$5.32 /

+1.225 (+29.91%)

, EB

Eventbrite

$10.51 /

+0.26 (+2.54%)

, DIOD

Diodes

$50.09 /

-0.31 (-0.62%)

, ICAD

iCAD

$12.31 /

-0.55 (-4.28%)

, TLRY

Tilray

$8.09 /

+0.305 (+3.92%)

, TME

Tencent Music

$11.43 /

+0.39 (+3.53%)

, AIMT

Aimmune

$17.89 /

+0.28 (+1.59%)

, SGMO

Sangamo

$9.08 /

+0.4 (+4.61%)

, HALO

Halozyme

$24.82 /

+1.24 (+5.26%)

, FATE

Fate Therapeutics

$30.30 /

+1.45 (+5.03%)

, PLYA

Playa Hotels & Resorts

$2.11 /

+0.06 (+2.93%)

, JCOM

j2 Global

$81.40 /

+0.03 (+0.04%)

, SGMS

Scientific Games

$12.97 /

-0.18 (-1.37%)

, MAXR

Maxar Technologies

$11.61 /

+0.37 (+3.29%)

, FSCT

ForeScout

$32.12 /

-0.08 (-0.25%)

, OMER

Omeros

$17.01 /

+0.99 (+6.18%)

, SCPL

SciPlay

$12.22 /

+0.33 (+2.78%)

, HTZ

Hertz

$3.18 /

-0.07 (-2.15%)

, AKBA

Akebia

$12.85 /

+0.86 (+7.17%)

, QTWO

Q2 Holdings

$81.58 /

-1.04 (-1.26%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
CBAY CymaBay
$1.84 /

+0.045 (+2.51%)

03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
03/13/20 Oppenheimer
CymaBay upgraded to Outperform from Perform at Oppenheimer
03/13/20 Cantor Fitzgerald
CymaBay upgraded to Overweight from Neutral at Cantor Fitzgerald
02/26/20 Citi
Citi upgrades Intercept to Buy on peak sales potential of Ocaliva
IIVI II-VI
$36.29 /

+0.45 (+1.26%)

03/23/20
Fly Intel: Top analyst initiations
03/23/20 Barclays
Barclays starts II-VI with Overweight rating, $31 price target
03/23/20 Barclays
II-VI initiated with an Overweight at Barclays
03/20/20 Craig-Hallum
II-VI price target lowered to $35 from $45 at Craig-Hallum
VRRM Verra Mobility
$9.12 /

+0.08 (+0.88%)

04/29/20 Credit Suisse
Verra Mobility price target lowered to $10.50 from $17 at Credit Suisse
03/18/20 Deutsche Bank
Verra Mobility price target lowered to $12 from $18 at Deutsche Bank
01/24/20 Credit Suisse
Credit Suisse sees more M&A in 2020 for FinTechs, processors and payments
01/23/20 Credit Suisse
Verra Mobility initiated with an Outperform at Credit Suisse
SGRY Surgery Partners
$10.82 /

-0.12 (-1.10%)

04/27/20 Benchmark
Surgery Partners upgraded to Buy on faster recovery timeline at Benchmark
04/27/20 Benchmark
Surgery Partners upgraded to Buy from Hold at Benchmark
04/21/20
Envision bankruptcy report has limited read-throughs, says Benchmark
03/24/20 RBC Capital
Surgery Partners price target lowered to $14 from $19 at RBC Capital
GDOT Green Dot
$30.78 /

-0.73 (-2.32%)

04/07/20 Craig-Hallum
Green Dot assumed with a Buy at Craig-Hallum
03/26/20 SunTrust
Green Dot price target lowered to $40 from $48 at SunTrust
03/26/20 BTIG
BTIG upgrades Green Dot to Buy on 'game-changer' CEO hire
03/25/20 BTIG
Green Dot upgraded to Buy from Neutral at BTIG
GO Grocery Outlet
$36.71 /

+0.01 (+0.03%)

01/29/20
Fly Intel: Top five analyst initiations
01/29/20 Craig-Hallum
Grocery Outlet initiated with a Buy at Craig-Hallum
11/12/19 Jefferies
Grocery Outlet comps remain well above industry trend, says Jefferies
08/14/19 Jefferies
Grocery Outlet price target raised to $50 from $41 at Jefferies
CZR Caesars
$9.65 /

-0.06 (-0.62%)

04/17/20 SunTrust
Caesars, Twin River Worldwide upgraded to Buy from Hold at SunTrust
04/17/20 SunTrust
Caesars upgraded to Buy from Hold at SunTrust
04/06/20 Jefferies
Eldorado has 'considerable upside' from Caesars merger, says Jefferies
04/03/20 Stifel
Eldorado Resorts shares offer 250% upside from current levels, says Stifel
NVAX Novavax
$24.59 /

+5.86 (+31.29%)

04/30/20 H.C. Wainwright
Novavax price target raised to $33 from $24 at H.C. Wainwright
04/24/20 B. Riley FBR
Novavax price target raised to $29 from $20 at B. Riley FBR
04/09/20 Ladenburg
Ladenburg ups Novavax target to $28 on 'potent' COVID vaccine candidate
03/27/20 B. Riley FBR
Novavax price target raised to $20 from $15 at B. Riley FBR
AMC AMC Entertainment
$5.32 /

+1.225 (+29.91%)

05/11/20 B. Riley FBR
Amazon buyout may not appeal to AMC shareholders, says B. Riley FBR
04/30/20 Imperial Capital
AMC Entertainment price target raised to $3 from $2 at Imperial Capital
04/23/20 Macquarie
AMC Entertainment downgraded to Neutral from Outperform at Macquarie
04/22/20 JPMorgan
JPMorgan downgrades EPR after only15% of April rents get collected
EB Eventbrite
$10.51 /

+0.26 (+2.54%)

04/03/20 SunTrust
Eventbrite price target lowered to $8 from $19 at SunTrust
02/28/20 SunTrust
Eventbrite price target lowered to $19 from $22 at SunTrust
02/28/20 RBC Capital
Eventbrite downgraded to Sector Perform from Outperform at RBC Capital
01/24/20 William Blair
Data shows Eventbrite fan engagement is growing, says William Blair
DIOD Diodes
$50.09 /

-0.31 (-0.62%)

04/17/20 Baird
Diodes upgraded to Outperform at Baird
04/17/20 Baird
Diodes upgraded to Outperform from Neutral at Baird
03/19/20 Wells Fargo
Diodes price target lowered to $55 from $64 at Wells Fargo
02/10/20 Baird
Baird removes 'Fresh Pick Designation' on Diodes for China disruptions
ICAD iCAD
$12.31 /

-0.55 (-4.28%)

02/13/20 Craig-Hallum
iCAD price target raised to $15 from $9 at Craig-Hallum
02/05/20 JMP Securities
iCAD initiated with an Outperform at JMP Securities
01/09/20 Lake Street
Lake Street starts 'disruptive' iCAD with Buy rating, $14 price target
12/20/19
iCAD initiated with a Buy at Dougherty
TLRY Tilray
$8.09 /

+0.305 (+3.92%)

04/16/20 Jefferies
Tilray downgraded to Underperform following 'short squeeze' at Jefferies
04/16/20 Jefferies
Tilray downgraded to Underperform from Hold at Jefferies
04/09/20 Consumer Edge
Tilray downgraded to Equal Weight from Overweight at Consumer Edge
04/08/20 Raymond James
Ontario AG order positive for Canadian cannabis stocks, says Raymond James
TME Tencent Music
$11.43 /

+0.39 (+3.53%)

03/18/20 BOCOM
Tencent Music upgraded to Neutral from Sell at BOCOM
03/12/20 Morgan Stanley
Tencent Music upgraded to Overweight from Equal Weight at Morgan Stanley
02/25/20 Goldman Sachs
Huya downgraded to Neutral on cost inflation at Goldman Sachs
02/19/20
Fly Intel: Top five analyst downgrades
AIMT Aimmune
$17.89 /

+0.28 (+1.59%)

04/06/20 Citi
DBV's Viaskin Peanut more likely than not to be approved, says Citi
04/06/20 Piper Sandler
Aimmune launch 'thrown a wrench' amid COVID-19, says Piper Sandler
03/23/20 Cantor Fitzgerald
Aimmune price target lowered to $32 from $64 at Cantor Fitzgerald
03/18/20 JMP Securities
Aimmune downgraded to Market Perform from Outperform at JMP Securities
SGMO Sangamo
$9.08 /

+0.4 (+4.61%)

02/28/20 William Blair
Biogen deal with Sangamo unlikely to have near-term impact, says William Blair
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
08/26/19
Fly Intel: Top five analyst initiations
08/26/19 H.C. Wainwright
Sangamo initiated with a Buy at H.C. Wainwright
HALO Halozyme
$24.82 /

+1.24 (+5.26%)

05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
02/05/20
Fly Intel: Top five analyst upgrades
02/05/20 Piper Sandler
Halozyme upgraded to Overweight from Neutral at Piper Sandler
FATE Fate Therapeutics
$30.30 /

+1.45 (+5.03%)

04/02/20 Piper Sandler
Fate Therapeutics price target raised to $63 from $57 at Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Citi
Fate Therapeutics price target raised to $41 from $26 at Citi
03/04/20 Barclays
Fate Therapeutics initiated with an Overweight at Barclays
PLYA Playa Hotels & Resorts
$2.11 /

+0.06 (+2.93%)

04/29/20 SunTrust
Playa Hotels & Resorts downgraded to Hold from Buy at SunTrust
04/29/20 SunTrust
Playa Hotels & Resorts downgraded to Hold from Buy at SunTrust
04/07/20 Citi
Playa Hotels & Resorts downgraded to Sell from Neutral at Citi
04/03/20 Deutsche Bank
Playa Hotels & Resorts price target lowered to $7 from $11 at Deutsche Bank
JCOM j2 Global
$81.40 /

+0.03 (+0.04%)

04/29/20
Fly Intel: Top five analyst initiations
04/29/20 JPMorgan
j2 Global initiated with an Overweight, $105 target at JPMorgan
04/29/20 JPMorgan
j2 Global initiated with an Overweight at JPMorgan
04/02/20
Fly Intel: Top five analyst initiations
SGMS Scientific Games
$12.97 /

-0.18 (-1.37%)

04/16/20 Jefferies
Gaming equipment suppliers 'managing around' fortunes of casinos, says Jefferies
04/15/20 Craig-Hallum
Scientific Games price target lowered to $20 from $55 at Craig-Hallum
02/20/20 Deutsche Bank
Scientific Games price target lowered to $23 from $29 at Deutsche Bank
02/19/20 Craig-Hallum
Scientific Games price target lowered to $55 from $60 at Craig-Hallum
MAXR Maxar Technologies
$11.61 /

+0.37 (+3.29%)

01/15/20 Credit Suisse
Maxar Technologies upgraded to Neutral from Underperform at Credit Suisse
01/08/20 JPMorgan
Maxar Technologies price target raised to $25 from $15 at JPMorgan
12/30/19 Raymond James
Maxar Technologies downgraded to Market Perform from Outperform at Raymond James
12/19/19 CIBC
Maxar Technologies upgraded to Neutral from Underperformer at CIBC
FSCT ForeScout
$32.12 /

-0.08 (-0.25%)

02/18/20 Baird
ForeScout acquired, Baird downgrades to Neutral
02/18/20 Baird
ForeScout downgraded to Neutral from Outperform at Baird
02/07/20 Berenberg
ForeScout downgraded to Hold from Buy at Berenberg
02/07/20 Monness Crespi
ForeScout downgraded to Neutral from Buy at Monness Crespi
OMER Omeros
$17.01 /

+0.99 (+6.18%)

03/04/20 Wedbush
Omeros price target raised to $22 from $18 at Wedbush
03/03/20 Cantor Fitzgerald
Omeros shares can 'significantly rerate' from here, says Cantor Fitzgerald
11/05/19 H.C. Wainwright
Omeros recent selloff appears unwarranted, says H.C. Wainwright
SCPL SciPlay
$12.22 /

+0.33 (+2.78%)

04/22/20 BofA
SciPlay upgraded to Neutral from Underperform at BofA
04/22/20 BofA
SciPlay upgraded to Neutral from Underperform at BofA
04/17/20 SunTrust
SciPlay upgraded to Buy at SunTrust as a 'stay-at-home play'
04/17/20 SunTrust
SciPlay upgraded to Buy from Hold at SunTrust
HTZ Hertz
$3.18 /

-0.07 (-2.15%)

05/05/20 Morgan Stanley
2020 may not be quite as bad as feared for used cars, says Morgan Stanley
04/27/20
Fly Intel: Top five analyst downgrades
04/27/20 Barclays
Barclays downgrades Hertz to Underweight on risk of capital call
04/27/20 Barclays
Hertz downgraded to Underweight from Equal Weight at Barclays
AKBA Akebia
$12.85 /

+0.86 (+7.17%)

05/06/20 RBC Capital
Akebia price target raised to $12 from $8 at RBC Capital
05/05/20 Piper Sandler
Piper Sandler remains a buyer of Akebia following Phase 3 INNO2VATE data
05/05/20 Piper Sandler
Piper says efficacy, safety of FibroGen, Akebia drugs 'quite similar' in DD-CKD
05/05/20 Piper Sandler
Piper sees Akebia shares having 'nice follow through' on pre-market upside
QTWO Q2 Holdings
$81.58 /

-1.04 (-1.26%)

05/08/20 RBC Capital
Q2 Holdings price target raised to $92 from $73 at RBC Capital
04/29/20
Fly Intel: Top five analyst upgrades
04/29/20 Baird
Q2 Holdings upgraded to Outperform at Baird
04/29/20 Baird
Q2 Holdings upgraded to Outperform from Neutral at Baird
  • 13
    May
  • 12
    May
Earnings
Surgery Partners reports Q1 EPS (76c), consensus (48c) » 16:17
05/11/20
05/11
16:17
05/11/20
16:17
SGRY

Surgery Partners

$10.84 /

-0.1 (-0.91%)

Reports Q1 revenue $441M,…

Reports Q1 revenue $441M, consensus $396.67M. "The full impact of COVID-19 on our operations and financial results will be driven by many factors, many of which remain uncertain or unknown. As our facilities begin to ramp up to more normal operating schedules, we will continue to be vigilant in our efforts to provide the safest possible environment for our colleagues, physician partners and patients. We are confident in our leadership, physicians and colleagues across the country as we reschedule postponed elective procedures and adapt to the evolving nature of this pandemic. In our new post-COVID-19 environment, we continue to be encouraged by the steady and consistent transition of surgeries to lower cost settings and we anticipate continued constructive engagement with health systems and health plans, who appreciate the quality, access and value of our model."

ShowHide Related Items >><<
SGRY Surgery Partners
$10.84 /

-0.1 (-0.91%)

04/27/20 Benchmark
Surgery Partners upgraded to Buy on faster recovery timeline at Benchmark
04/27/20 Benchmark
Surgery Partners upgraded to Buy from Hold at Benchmark
04/21/20
Envision bankruptcy report has limited read-throughs, says Benchmark
03/24/20 RBC Capital
Surgery Partners price target lowered to $14 from $19 at RBC Capital
Upgrade
Surgery Partners upgraded to Buy on faster recovery timeline at Benchmark » 06:43
04/27/20
04/27
06:43
04/27/20
06:43
SGRY

Surgery Partners

$9.96 /

+0.12 (+1.22%)

Benchmark analyst Bill…

Benchmark analyst Bill Sutherland upgraded Surgery Partners to Buy from Hold with a $14 price target. He sees an easing of restrictions, in some cases sooner than previously thought, in states and municipalities where Surgery Partners has facilities, Sutherland tells investors. He adds that he now thinks the company's volumes could begin to improve from early April levels, which was ahead of his prior expectation. He does acknowledge that the volume growth driven by the growing backlog of deferred cases will be partially offset by the impact of a softer economy on demand, arguing that his $14 price target factors in the remaining risks and uncertainties in the trajectory of the company's recovery.

ShowHide Related Items >><<
SGRY Surgery Partners
$9.96 /

+0.12 (+1.22%)

04/27/20 Benchmark
Surgery Partners upgraded to Buy from Hold at Benchmark
04/21/20
Envision bankruptcy report has limited read-throughs, says Benchmark
03/24/20 RBC Capital
Surgery Partners price target lowered to $14 from $19 at RBC Capital
03/16/20 Citi
Surgery Partners 58% selloff since Q4 results overdone, says Citi
Upgrade
Surgery Partners upgraded to Buy from Hold at Benchmark » 06:34
04/27/20
04/27
06:34
04/27/20
06:34
SGRY

Surgery Partners

$9.96 /

+0.12 (+1.22%)

Benchmark analyst Bill…

Benchmark analyst Bill Sutherland upgraded Surgery Partners to Buy from Hold with a $14 price target.

ShowHide Related Items >><<
SGRY Surgery Partners
$9.96 /

+0.12 (+1.22%)

04/21/20
Envision bankruptcy report has limited read-throughs, says Benchmark
03/24/20 RBC Capital
Surgery Partners price target lowered to $14 from $19 at RBC Capital
03/16/20 Citi
Surgery Partners 58% selloff since Q4 results overdone, says Citi
03/06/20 RBC Capital
Surgery Partners price target lowered to $19 from $22 at RBC Capital
Recommendations
Envision bankruptcy report has limited read-throughs, says Benchmark » 11:54
04/21/20
04/21
11:54
04/21/20
11:54
AMN

AMN Healthcare

$50.04 /

-4.98 (-9.05%)

, CCRN

Cross Country Healthcare

$5.37 /

-0.55 (-9.29%)

, SGRY

Surgery Partners

$9.20 /

-0.08 (-0.86%)

, KKR

KKR

$21.76 /

-1.195 (-5.21%)

After Bloomberg reported…

After Bloomberg reported this morning that Envision Healthcare, which is privately-held by KKR (KKR), has hired restructuring advisers and is contemplating a bankruptcy filing, Benchmark analyst Bill Sutherland said he thinks Envision's troubles have limited applicability or read-through to AMN Healthcare (AMN), Cross Country Healthcare (CCRN) or Surgery Partners (SGRY). Envision is suffering from a decline in procedures related to both their hospital anesthesiology business and ASCs, but he believes Surgery Partners' footprint of ASCs is advantaged with a focus in the Southeast and Midwest, Sutherland tells investors. Envision has been challenged in the last few years with the process of moving its provider groups to in-network status with payers, added the analyst, who said that on net for AMN and Cross Country Healthcare he believes that COVID-19's impact has meant a bit more demand and better bill rates.

ShowHide Related Items >><<
AMN AMN Healthcare
$50.04 /

-4.98 (-9.05%)

03/31/20 Sidoti
AMN Healthcare pullback offers attractive entry point, Sidoti says in upgrade
03/31/20 Sidoti
AMN Healthcare upgraded to Buy from Neutral at Sidoti
03/26/20 SunTrust
AMN Healthcare downgraded to Hold from Buy at SunTrust
03/26/20 SunTrust
AMN Healthcare downgraded to Hold from Buy at SunTrust
CCRN Cross Country Healthcare
$5.37 /

-0.55 (-9.29%)

SGRY Surgery Partners
$9.20 /

-0.08 (-0.86%)

03/24/20 RBC Capital
Surgery Partners price target lowered to $14 from $19 at RBC Capital
03/16/20 Citi
Surgery Partners 58% selloff since Q4 results overdone, says Citi
03/06/20 RBC Capital
Surgery Partners price target lowered to $19 from $22 at RBC Capital
03/03/20
Fly Intel: Top five analyst downgrades
KKR KKR
$21.76 /

-1.195 (-5.21%)

04/17/20 BMO Capital
BlackRock price target raised to $441 from $386 at BMO Capital
04/15/20 Wells Fargo
KKR price target lowered to $33 from $38 at Wells Fargo
02/03/20
Fly Intel: Top five analyst upgrades
02/03/20 Barclays
Barclays upgrades KKR to Overweight, boosts price target to $37
Over a quarter ago
Recommendations
Surgery Partners price target lowered to $14 from $19 at RBC Capital » 06:54
03/24/20
03/24
06:54
03/24/20
06:54
SGRY

Surgery Partners

$5.44 /

+0.2 (+3.82%)

RBC Capital analyst Frank…

RBC Capital analyst Frank Morgan lowered the firm's price target on Surgery Partners to $14 from $19 but keeps an Outperform rating on the shares. The analyst cites the company's withdrawal of guidance and drawdown of credit revolver, noting that amid a near-shutdown in elective procedure, it is going into "defensive mode". Morgan adds that Surgery Partners' exposure may be mitigated somewhat considering the high percentage of high-acuity cases that go through its surgical hospitals, but he sees the defensive actions to ensure financial flexibility as prudent.

ShowHide Related Items >><<
SGRY Surgery Partners
$5.44 /

+0.2 (+3.82%)

03/16/20 Citi
Surgery Partners 58% selloff since Q4 results overdone, says Citi
03/06/20 RBC Capital
Surgery Partners price target lowered to $19 from $22 at RBC Capital
03/03/20
Fly Intel: Top five analyst downgrades
03/03/20 Benchmark
Surgery Partners downgraded to Hold on near-term volume worries at Benchmark
Recommendations
Surgery Partners 58% selloff since Q4 results overdone, says Citi » 06:45
03/16/20
03/16
06:45
03/16/20
06:45
SGRY

Surgery Partners

$6.39 /

-0.63 (-8.97%)

Surgery Partners shares…

Surgery Partners shares have fallen over 58% since the company reported Q4 earnings on uncertainty related to the coronavirus as well as the company's weaker cash flow and high leverage profile, Citi analyst Ralph Giacobbe tells investors in a research note. The analyst, however, believes the stock has "overcorrected" for a company that should see continued long-term growth. In addition, its balance sheet, with credit agreement flexibility, should allow Surgery Partners "to navigate barring extreme circumstances," says Giacobbe. The analyst reduced the firm's price target to $10 from $20 and maintains a Buy rating on the shares.

ShowHide Related Items >><<
SGRY Surgery Partners
$6.39 /

-0.63 (-8.97%)

03/06/20 RBC Capital
Surgery Partners price target lowered to $19 from $22 at RBC Capital
03/03/20
Fly Intel: Top five analyst downgrades
03/03/20 Benchmark
Surgery Partners downgraded to Hold on near-term volume worries at Benchmark
03/03/20 Benchmark
Surgery Partners downgraded to Hold from Buy at Benchmark
Recommendations
Surgery Partners price target lowered to $19 from $22 at RBC Capital » 07:35
03/06/20
03/06
07:35
03/06/20
07:35
SGRY

Surgery Partners

$12.19 /

-3.1 (-20.27%)

RBC Capital analyst Frank…

RBC Capital analyst Frank Morgan lowered the firm's price target on Surgery Partners to $19 from $22 but keeps an Outperform rating on the shares. The analyst notes that while the company's Q4 results were "decent" and in line with the management's guidance, he also cautions that generating positive net cash flow for Surgery Partners remains a challenge for the near term which amid concerns over potential coronavirus impact on demand for elective procedures. Morgan adds however that the company's outlook is consistent with prior commentary and the long-term growth targets as the management's "strategic initiatives continue to deliver improved performance".

ShowHide Related Items >><<
SGRY Surgery Partners
$12.19 /

-3.1 (-20.27%)

03/03/20
Fly Intel: Top five analyst downgrades
03/03/20 Benchmark
Surgery Partners downgraded to Hold on near-term volume worries at Benchmark
03/03/20 Benchmark
Surgery Partners downgraded to Hold from Buy at Benchmark
01/14/20 Benchmark
Surgery Partners price target raised to $19 from $13 at Benchmark
Earnings
Surgery Partners expects to grow 2020 revenues at high single-digit percentage » 07:13
03/05/20
03/05
07:13
03/05/20
07:13
SGRY

Surgery Partners

$15.29 /

+0.55 (+3.73%)

Consensus $1.94B. The…

Consensus $1.94B. The Company projects that it will be able to grow revenues at a high single-digit percentage rate and Adjusted EBITDA at a double-digit percentage rate in 2020, excluding impacts from Idaho Falls Community Hospital, which opened in November 2019.

ShowHide Related Items >><<
SGRY Surgery Partners
$15.29 /

+0.55 (+3.73%)

03/03/20
Fly Intel: Top five analyst downgrades
03/03/20 Benchmark
Surgery Partners downgraded to Hold on near-term volume worries at Benchmark
03/03/20 Benchmark
Surgery Partners downgraded to Hold from Buy at Benchmark
01/14/20 Benchmark
Surgery Partners price target raised to $19 from $13 at Benchmark
Earnings
Surgery Partners reports Q3 EPS (57c), consensus 12c » 07:12
03/05/20
03/05
07:12
03/05/20
07:12
SGRY

Surgery Partners

$15.29 /

+0.55 (+3.73%)

Reports Q4 revenue…

Reports Q4 revenue $520.7M, consensus $514.61M. Eric Evans, Chief Executive Officer of Surgery Partners, stated, "Our fourth quarter results reflect continued strong top-line growth and margin expansion that has enabled us to achieve our full year target of double-digit Adjusted EBITDA growth. For the sixth quarter in a row, we grew days adjusted same-facility revenues, either achieving the high-end or exceeding our long-term growth target of 4-6%. We continue to see momentum stemming from Medicare's November announcement approving total knee replacement and certain cardiac procedures in ASCs beginning this year. We have also continued to expand operating rooms and recruit physicians who perform these procedures to capture this opportunity. The steady and consistent transition of surgeries to lower cost settings provides further proof of our continued constructive engagement with health plans, who appreciate the quality, access and value of our model."

ShowHide Related Items >><<
SGRY Surgery Partners
$15.29 /

+0.55 (+3.73%)

03/03/20
Fly Intel: Top five analyst downgrades
03/03/20 Benchmark
Surgery Partners downgraded to Hold on near-term volume worries at Benchmark
03/03/20 Benchmark
Surgery Partners downgraded to Hold from Buy at Benchmark
01/14/20 Benchmark
Surgery Partners price target raised to $19 from $13 at Benchmark

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.